advanced or metastatic RCC- patient profiles
KEYTRUDA® in RCC
Explore KEYTRUDA® patient profiles
Meet Natasha*
A patient with RCC with an intermediate-high risk of recurrence
Background info
- 61 years of age; retired principal
- Married; 3 grandchildren
- ECOG PS=0
Natasha’s* clinical presentation
Symptoms
- Intermittent flank pain over the past 6 months
Imaging/biopsy and results
- Abdominal CT scan revealed a 7.5-cm tumour on right kidney
Diagnosis
- RCC
Treatment
- Radical complete nephrectomy
Disease risk category
- Intermediate-high: pT3, without nodal involvement (N0) or distant metastases (M0)
Explore efficacy and safety profile results for KEYTRUDA® for the adjuvant treatment of adults with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Provide your patients with information regarding their treatment of adjuvant RCC with KEYTRUDA®
Meet Joe*
A patient with metastatic RCC
Background info
- Hypertension and diabetes, currently managed with medication
Joe’s* clinical presentation
Blood work and results
-
Hemoglobin, corrected calcium, platelets, and neutrophils all within normal range
Imaging/biopsy and results
- Imaging found a 5.5-cm lesion in the left kidney; biopsy came back as a Grade 4 RCC
-
CTs show bone metastases to spine and large retroperitoneal nodes
Other assessments
- Karnofsky performance status: 70%
-
IMDC risk: intermediate
Diagnosis: metastatic RCC
Explore efficacy and safety profile results for KEYTRUDA® in combination
with axitinib for advanced or metastatic RCC naïve to treatment.
v
Explore efficacy and safety profile results for KEYTRUDA® in combination with LENVIMA® for the treatment of advanced or metastatic RCC.
* Hypothetical patient. May not be representative of all patients.
CT=computed tomography; ECOG PS=Eastern Cooperative Oncology Group performance status; IMDC=International Metastatic RCC Database Consortium; M=metastases; N=node; pT=pathological tumour; RCC=renal cell carcinoma.
References:
1. KEYTRUDA® Product Monograph. Merck Canada Inc. December 2, 2024.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer. V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 25, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.
3. Ljungberg B, Bex A, Albiges L, et al. EAU guidelines on renal cell carcinoma. European Association of Urology; 2024. Accessed November 8, 2024. https://uroweb.org/guidelines/renal-cell-carcinoma.
© 2023, 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
CA-RCC-00232